A Phase 4 interventional study of Aripiprazole and Placebo in Irritability Associated With Autistic Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 38 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.
Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 4, and was the 11th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
This study's enrollment of 215 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 81 across the 15 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2011, is the only one in phase 4, and was the 4th registered.
Otsuka Holdings Co., Ltd.’s Autistic Disorder studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing aripiprazole in Autistic Disorder, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 11 in Autistic Disorder:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aripiprazole
Drug: Placebo
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
Also known as: BMS-337039, Abilify
Tablets, oral, 0 mg, once daily, 16 weeks
Percentage of Patients Relapsing by Week 16
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a\&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a\&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.
Time frame: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.
Time frame: From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to \<=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.
Time frame: From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Up to 26 weeks
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
| Milestone | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Started | 157 | 0 |
| Received treatment | 155 | 0 |
| Completed | 85 | 0 |
| Not completed | 72 | 0 |
| Withdrew: Adverse event | 12 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Lost to follow-up | 8 | 0 |
| Withdrew: Sponsor's administrative reason | 11 | 0 |
| Withdrew: No longer meets study criteria | 7 | 0 |
| Withdrew: Lack of efficacy | 25 | 0 |
| Withdrew: Poor compliance/noncompliance | 2 | 0 |
| Milestone | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Started | 41 | 44 |
| Received treatment | 39 | 43 |
| Completed | 22 | 19 |
| Not completed | 19 | 25 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Lack of efficacy | 13 | 23 |
| Withdrew: Poor compliance/noncompliance | 0 | 1 |
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a\&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a\&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.
| Percentage of participants | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Percentage of Patients Relapsing by Week 16 | 32 (NA to NA) | 50 (42 to NA) |
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.
| Units on a scale | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF]) | 5.2 ± 1.61 | 9.6 ± 1.56 |
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to \<=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.
| Units on a scale | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF]) | 4.2 ± 0.26 | 4.8 ± 0.26 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) |
|---|---|
| Death | 0 |
| SAEs | 1 |
| AEs leading to discontinuation | 13 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| Participants | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo |
|---|---|---|
| Death | 0 | 0 |
| SAEs | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 |
| Treatment-related AEs | 9 | 6 |
Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole, 2-15 mg (Phase 1) | 0/157 (0%) | 1/155 (0.6%) | 112/155 (72.3%) |
| Aripiprazole, 2-15 mg (Phase 2) | 0/41 (0%) | 0/39 (0%) | 11/39 (28.2%) |
| Placebo (Phase 2 Only) | 0/44 (0%) | 0/43 (0%) | 5/43 (11.6%) |
| Event | Aripiprazole, 2-15 mg (Phase 1) | Aripiprazole, 2-15 mg (Phase 2) | Placebo (Phase 2 Only) |
|---|---|---|---|
| AggressionPsychiatric disorders | 1/155 | 0/39 | 0/43 |
| Event | Aripiprazole, 2-15 mg (Phase 1) | Aripiprazole, 2-15 mg (Phase 2) | Placebo (Phase 2 Only) |
|---|---|---|---|
| Weight increasedInvestigations | 39/155 | 0/39 | 0/43 |
| SomnolenceNervous system disorders | 23/155 | 0/39 | 0/43 |
| VomitingGastrointestinal disorders | 22/155 | 2/39 | 2/43 |
| Increased appetiteMetabolism and nutrition disorders | 20/155 | 1/39 | 2/43 |
| Upper respiratory tract infectionInfections and infestations | 16/155 | 4/39 | 1/43 |
| FatigueGeneral disorders | 13/155 | 1/39 | 0/43 |
| InsomniaPsychiatric disorders | 13/155 | 1/39 | 1/43 |
| DiarrhoeaGastrointestinal disorders | 11/155 | 1/39 | 0/43 |
| TremorNervous system disorders | 10/155 | 1/39 | 1/43 |
| NasopharyngitisInfections and infestations | 9/155 | 1/39 | 1/43 |
All participants who were randomized to receive treatment in Phase 2.
| Age, Continuous(years) | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo | Total |
|---|---|---|---|
| Mean | 10.1 ± 2.80 | 10.8 ± 2.77 | 10.4 ± 2.79 |
| Sex: Female, Male(Participants) | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo | Total |
|---|---|---|---|
| Female | 11 | 6 | 17 |
| Male | 30 | 38 | 68 |
| Race/Ethnicity, Customized(Participants) | Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 11 | 19 |
| White | 31 | 28 | 59 |
| Other | 2 | 1 | 3 |
Ran from Mar 2011 to primary completion in Jun 2012, 15 months.
Results were first posted in May 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →